By Fineline Cube Hansoh Pharmaceutical Group Co., Ltd. (HKG: 3692) has announced that its investigational antibody-drug conjugate (ADC), HS-20093, has been granted its fourth Breakthrough Therapy Designation (BTD) by China’s National Medical Products Administration (NMPA). The latest designation is for its use in combination with adebrelimab for the treatment of locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) with negative driver genes that has progressed or recurred after prior platinum-based chemotherapy.
Regulatory Milestone Timeline
| Date | Indication | Therapy Type |
|---|---|---|
| Nov 2024 | Extensive-stage small cell lung cancer (ES-SCLC) post first-line therapy | Monotherapy |
| Feb 2025 | Osteosarcoma post ≥2 lines of therapy | Monotherapy |
| Apr 2025 | Non-squamous NSCLC post platinum chemo | Monotherapy |
| Apr 2026 | Non-squamous NSCLC post platinum chemo | Combination with adebrelimab |
Asset Profile & Development Strategy
- Molecule: HS-20093, a B7-H3-targeted antibody-drug conjugate (ADC).
- Target: B7-H3 (CD276), an immune checkpoint protein overexpressed across many solid tumors.
- Clinical Program: Actively being studied in multiple Phase II/III trials in China for lung cancer (NSCLC & SCLC), sarcoma, head and neck cancer, and other solid tumors.
- Strategic Shift: The latest BTD marks a significant evolution from monotherapy to a rational combination strategy with Hansoh’s own PD-L1 inhibitor, adebrelimab, aiming to enhance anti-tumor efficacy in a difficult-to-treat NSCLC population.
Strategic Significance
This fourth BTD for HS-20093 highlights the NMPA’s recognition of the asset’s substantial potential across a broad spectrum of cancers. The move into combination therapy for NSCLC is particularly strategic, as it leverages Hansoh’s internal pipeline to create a potentially best-in-class regimen for patients who have exhausted standard chemotherapy options. This approach not only addresses a major unmet medical need but also strengthens Hansoh’s position in the highly competitive Chinese oncology market.
Forward-Looking Statements
This brief contains forward-looking statements regarding the development and regulatory pathway of HS-20093. The granting of BTD status does not guarantee approval, and clinical trial outcomes are subject to significant risk and uncertainty.-Fineline Info & Tech